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Purpose. Although currently classiﬁed as variants of follicular neoplasms (FNs), Hürthle cell neoplasms (HCNs) exhibit distinct
biological characteristics. Hence, the metabolism of both neoplasms may also be diﬀerent. The aims of this study were to
investigate and compare the expression of glycolysis-related proteins in HCNs and FNs and to determine the clinical
implications of such expression. Methods. Tissue microarrays were constructed with 265 samples of FNs (112 follicular
carcinomas (FCs) and 153 follicular adenomas (FAs)) as well as 108 samples of HCNs (27 Hürthle cell carcinomas (HCCs) and
81 Hürthle cell adenomas (HCAs)). Immunohistochemical staining for the glycolysis-related molecules Glut-1, hexokinase II,
CAIX, and MCT4 was performed. Results. The expression levels of Glut-1, hexokinase II, CAIX, and MCT4 were signiﬁcantly
higher in HCNs than in FNs (p < 0 001). Glut-1, hexokinase II, CAIX, and MCT4 expression levels were highest in HCC,
followed by HCA, FC, and FA (all p < 0 001). In HCC, hexokinase II positivity was associated with large tumor size
(>4 cm) (p = 0 046), CAIX positivity with vascular invasion (p = 0 005), and MCT4 positivity with extrathyroidal extension
(p = 0 030). Conclusion. The expression levels of the glycolysis-related proteins Glut-1, hexokinase II, CAIX, and MCT4
were higher in HCNs than in FNs and in HCCs than in HCAs.
1. Introduction
The metabolism of malignant tumors is characterized by the
Warburg eﬀect, in which a metabolic shift from oxidative
phosphorylation in the mitochondria towards glycolysis
occurs in tumor cells [1]. Key molecules involved in regulat-
ing glycolysis and its products include Glut-1, hexokinase II,
CAIX, and MCT4. Glut-1 is a glucose transporter [2] while
hexokinase II is the initiating enzyme in glycolysis that
phosphorylates glucose to produce glucose-6-phosphate [3].
CAIX leads to the reversible hydration of carbon dioxide to
neutralize the acidiﬁcation caused by lactate formed during
glycolysis [4], and the MCT4 channel exports lactate
produced by glycolysis out of the cell [5].
Currently, the World Health Organization classiﬁes
Hürthle cell neoplasm (HCN) as an oncocytic variant of
follicular neoplasm (FN) [6]. Hürthle cells are considered
an oxyphilic variant of follicular epithelial cells and are
characterized by large-sized cells with polygonal to square
shapes, distinct borders, hyperchromatic nuclei with promi-
nent nucleoli, and abundant eosinophilic granular cytoplasm
owing to the accumulation of large numbers of intracytoplas-
mic mitochondria. Hürthle cell adenomas (HCAs) account
for 10–15% of follicular adenomas (FAs), while Hürthle cell
carcinomas (HCCs) comprise 20–25% of follicular carcino-
mas (FCs) [7]; however, several studies have suggested that
HCN could be a distinct disease. The rate of malignancy in
FNs ranges from 15% to 30%, compared to a higher rate of
25–45% in HCNs [8–12]. Compared to FC, HCC is prone
to metastasize to the lymph nodes, soft tissues of the neck,
[13], and distant sites [14] and exhibits a higher rate of resis-
tance to iodine therapy. Therefore, the prognosis of HCC is
poor; this disease carries a higher rate of recurrence and
mortality [14–17]. Furthermore, genomic analysis of HCCs
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suggests that it may represent a unique class of thyroid malig-
nancies [18], and molecular studies revealed that the TERT
C228T promoter mutation is common in HCNs [19].
While HCN and FN tumors exhibit diﬀerent biological
characteristics, a previous study using [18F]-2-ﬂuoro-2-
deoxy-D-glucose (18F-FDG) positron emission tomography
(PET) also showed that HCAs exhibit higher focal 18F-FDG
uptakes and maximum standardized update values (SUV-
max) than FAs [20]. Therefore, it could be speculated that
the metabolic features of HCN and FN diﬀer; however, this
has not been researched extensively to date. In a previous
study, we have demonstrated diﬀerential expression of
glycolysis-related protein among diﬀerent types of thyroid
cancer [21]. Therefore, the aims of this study were to
investigate the expression of glycolysis-related proteins in
HCN and FN and to examine the clinical implications of
any diﬀerences in expression levels.
2. Materials and Methods
2.1. Patient Selection. Patients who were diagnosed with FN
and HCN after surgery at the Severance Hospital between
January 2000 and December 2013 and with available paraﬃn
blocks and slides for histologic evaluation were included in
this study. All cases were retrospectively reviewed by a
thyroid pathologist (JSK), and histological evaluation was
performed after hematoxylin and eosin staining. Clinico-
pathologic data were obtained from the patients’ medical
records and included age at diagnosis, disease recurrence,
metastasis, current status, and duration of follow-up. The
tumor size, location (right or left lobe), extent (conﬁned
to the thyroid parenchyma or with extrathyroidal spread),
and number of metastatic lymph nodes were also noted
after reviewing the slides and surgical pathology reports.
This study was approved by the Institutional Review
Board of Yonsei University Severance Hospital.
2.2. Tissue Microarray. Representative areas were selected on
hematoxylin and eosin-stained slides, and a corresponding
spot was marked on the surface of the matching paraﬃn
block. Three-millimeter-sized tissue cores were extracted by
using a manual tissue arrayer from the selected areas and
placed into a 6× 5 recipient block. More than two tissue cores
were extracted from each sample to minimize extraction bias.
Each tissue core was assigned a unique tissue microarray
location number that was linked to a database containing
other clinicopathologic data.
2.3. Immunohistochemistry. Antibodies used for immunohis-
tochemistry are listed in Table 1. All immunohistochemistry
was performed with formalin-ﬁxed, paraﬃn-embedded tis-
sue sections using an automatic immunohistochemistry
staining device (Benchmark XT, Ventana Medical System,
Tucson, AZ, USA). Brieﬂy, 5μm-thick formaldehyde-ﬁxed
paraﬃn-embedded tissue sections were transferred onto
adhesive slides and dried at 62°C for 30 minutes. Standard
heat epitope retrieval was performed for 30 minutes in
ethylene diamine tetraacetic acid, pH 8.0, in the autostainer.
The samples were then incubated with primary antibodies.
Afterwards, the sections were incubated with biotinylated
anti-mouse immunoglobulins, peroxidase-labeled streptavi-
din (LSAB Kit, DakoCytomation), and 3,30-diaminobenzi-
dine. Negative control samples were processed without the
primary antibody. Positive control tissues were used as per
the manufacturer’s recommendation. Slides were counter-
stained with Harris hematoxylin. Optimal primary antibody
incubation times and concentrations were determined by
serial dilutions of each immunohistochemical assay using a
tissue block ﬁxed and embedded exactly as performed for
the samples.
2.4. Interpretation of Immunohistochemical Staining. Immu-
nohistochemical markers were accessed by light microscopy.
The stained slides were semiquantitatively evaluated as previ-
ously described [22]. Tumor cell staining was assessed as 0:
negative or weak immunostaining in <1% of the tumor cells,
1: focal expression in 1–10% of tumor cells, 2: positive in
11–50% of tumor cells, and 3: positive in 51–100% of
tumor cells. These evaluations were applied over the entire
area of the tumor, which was scored as follows; 0-1: negative,
2: low-positive, and 3: high-positive. For the Ki-67 labeling
index (Ki-67 L.I.), grading was performed as previously
described, with some modiﬁcations [23, 24]. Tumor cells
with Ki-67 L.I.< 3% was graded as 0, 3%≤Ki-67 L.I.≤ 5%
as 1, and 5%<Ki-67 L.I. as 2. “Glycolysis type” samples were
deﬁned as those positive for two or more of the markers
Glut-1, hexokinase II, CAIX, and MCT4; otherwise, the
sample was deﬁned as nonglycolysis type.
2.5. Statistical Analysis. Data were analyzed using IBM SPSS
Statistics for Windows, Version 21.0 (IBM Corp. Released
2012, Armonk, NY, USA). For determination of statistical
signiﬁcance, the Student’s t-test and Fisher’s exact test were
used for continuous and categorical variables, respectively.
For analyzing data with multiple comparisons, a corrected
p value with the application of the Bonferroni multiple com-
parison procedure was used. Correlation among glycolysis-
Table 1: Source, clone, and dilution of antibodies used in this study.
Antibody Clone Dilution Company
Glut-1 SPM498 1 : 200 Abcam, Cambridge, UK
Hexokinase II 3D3 1 : 200 Abcam, Cambridge, UK
CAIX Polyclonal 1 : 100 Abcam, Cambridge, UK
MCT4 Polyclonal 1 : 100 Santa Cruz, CA, USA
Ki-67 MIB-1 1 : 150 Dako, Denmark AS, Glostrup, Denmark
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related proteins, clinicopathologic factors, and Ki-67 L.I. was
compared using the Spearman’s rho. Statistical signiﬁcance
was set to p < 0 05. Cox proportional hazards model with
univariate and multivariate analyses was used to evaluate
the prognostic factors for disease-free and overall survival.
3. Results
3.1. Basal Characteristic of Follicular Neoplasms and Hürthle
Cell Neoplasms. This study included 265 patients with FN:
153 with FA and 112 with FC. Of the 112 FCs, 99 cases
were of the minimally invasive type and 13 were widely
invasive. Clinicopathologic features of the FCs are pre-
sented in Supplementary Table 1 available online at
https://doi.org/10.1155/2017/6230294. Additionally, 108
patients with HCN were included, 81 with HCA and 27
with HCC. The clinicopathologic features of HCN are
presented in Supplementary Table 1.
3.2. Expression of Glycolysis-Related Proteins in Follicular
Neoplasms and Hürthle Cell Neoplasms. The expression of
Glut-1, hexokinase II, CAIX, and MCT4 was signiﬁcantly
higher in HCNs than in FNs (p < 0 001, Table 2 and
Figure 1). When comparing the expression of glycolysis-
related proteins between FA, FC, HCA, and HCC, Glut-1,
hexokinase II, CAIX, and MCT4 expression was highest in
HCC, followed by HCA, FC, and FA (all p < 0 001, Table 3
and Figure 2). Furthermore, the number of positive markers
among the four glycolysis-related markers was examined in
FA, FC, HCA, and HCC. The percentage of cases with the
number of positive markers was the highest in HCC,
followed by HCA, FC, and FA (Table 4 and Figure 3). The
ratio of glycolysis type was the highest in HCC, followed by
HCA, FC, and FA (Figure 4).
3.3. Correlation between the Expression of Glycolysis-Related
Proteins and Clinicopathologic Factors in Hürthle Cell
Carcinoma. We investigated the correlation between the
expression of glycolysis-related proteins and clinicopatho-
logic factors in HCC. Hexokinase II positivity was associated
with large tumor size (>4 cm) (r = 0 384, p = 0 046), CAIX
positivity with vascular invasion (r = 0 545, p = 0 005), and
MCT4 positivity with extrathyroidal extension (r = 0 418,
p = 0 030) (Figure 5).
3.4. Correlation between the Expression of Glycolysis-Related
Proteins and Ki-67 Labeling Index in Follicular Carcinoma
and Hürthle Cell Carcinoma. Next, we evaluated the correla-
tion between Ki-67 L.I. and the expression of glycolysis-
related proteins in FC and HCC. Correlation analysis showed
that Ki-67 L.I. was related to MCT4 in FC (r = 0 187,
p = 0 048) and GLUT1 expression (r = 0 419, p = 0 029) in
HCC (Table 5).
3.5. The Impact of the Expression of Glycolysis-Related
Proteins on Prognosis. Finally, we investigated the impact of
the clinical parameters and the expression of glycolysis-
related proteins in the clinical outcomes of patients with FC
and HCC. During the follow-up period, 11 patients experi-
ence disease recurrence, while 5 patients had suﬀered death.
Table 2: Expression of glycolysis-related proteins in follicular neoplasms and Hürthle cell neoplasms.
Parameters Total N = 373 % Follicular neoplasm n = 265 % Hürthle cell neoplasm n = 108 % p value
GLUT-1 <0.001
Negative 349 (93.6) 263 (99.2) 86 (79.6)
Positive 24 (6.4) 2 (0.8) 22 (20.4)
Hexokinase II <0.001
Negative 289 (77.5) 229 (86.4) 60 (55.6)
Positive 84 (22.5) 36 (13.6) 48 (44.4)
CAIX <0.001
Negative 348 (93.3) 263 (99.2) 85 (78.7)
Positive 25 (6.7) 2 (0.8) 23 (21.3)
MCT4 <0.001
Negative 279 (74.8) 215 (81.1) 64 (59.3)
Positive 94 (25.2) 50 (18.9) 44 (40.7)
Negative
FA
Glut-1
Hexokinase II
CAIX
MCT-4
FC HCA HCC
Positive
Figure 1: Heat map of glycolysis-related proteins found in follicular neoplasms and Hürthle cell neoplasms. (FA: follicular adenoma;
FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma).
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Figure 2: Expression of glycolysis-related proteins in follicular neoplasms and Hürthle cell neoplasms. The expression of Glut-1, hexokinase
II, CAIX, andMCT4 was signiﬁcantly higher in Hürthle cell neoplasms compared to follicular neoplasms and in Hürthle cell carcinomas than
in Hürthle cell adenomas. (FA: follicular adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma).
Table 3: Expression of glycolysis-related proteins in follicular neoplasms and Hürthle cell neoplasms.
Parameters
Follicular neoplasm n = 265 % Hürthle cell neoplasm n = 108 %
p value
FA n = 153 % FC n = 112 % HCA n = 81 % HCC n = 27 %
GLUT-1 <0.001
Negative 152 (99.3) 111 (99.1) 70 (86.4) 16 (59.3)
Positive 1 (0.7) 1 (0.9) 11 (13.6) 11 (40.7)
Hexokinase II <0.001
Negative 140 (91.5) 89 (79.5) 52 (64.2) 8 (29.6)
Positive 13 (8.5) 23 (20.5) 29 (35.8) 19 (70.4)
CAIX <0.001
Negative 153 (100.0) 110 (98.2) 66 (81.5) 19 (70.4)
Positive 0 (0.0) 2 (1.8) 15 (18.5) 8 (29.6)
MCT4 (T) <0.001
Negative 132 (86.3) 83 (74.1) 49 (60.5) 15 (55.6)
Positive 21 (13.7) 29 (25.9) 32 (39.5) 12 (44.4)
FA: follicular adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma.
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In multivariate analysis, female sex (OR 0.201, 95% CI
0.061-0.060, p = 0 008) and extrathyroidal extension (OR
4.937, 95% CI 1.503–16.208, p = 0 008) was related to
disease-free survival (Table 6), while only lymph node
metastasis (OR 15.742, 95% CI 1.723–143.770, p = 0 014)
was related to overall survival (Table 7). However, the
Table 4: Number of positive markers for glycolysis in follicular neoplasms and Hürthle cell neoplasms.
Parameter Total N = 373 % FA n = 153 % FC n = 112 % HCA n = 84 % HCC n = 27 % p value
Number of positive
markers for glycolysis
<0.001
0 215 (57.6) 120 (78.4) 67 (59.8) 26 (32.1) 2 (7.4)
1 111 (29.8) 33 (21.6) 36 (32.1) 33 (40.7) 9 (33.3)
2 28 (7.5) 0 (0.0) 8 (7.1) 12 (14.8) 8 (29.6)
3 18 (4.8) 0 (0.0) 1 (0.9) 10 (12.3) 7 (25.9)
4 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.7)
FA: follicular adenoma; FC: follicular carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma.
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Figure 3: Number of positive glycolytic markers in follicular neoplasms and Hürthle cell neoplasms. (FA: follicular adenoma; FC: follicular
carcinoma; HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma).
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expression of glycolysis-related proteins Glut-1, hexokinase
II, CAIX, and MCT4 levels was not signiﬁcantly related to
disease-free and overall survival (Tables 6 and 7).
4. Discussion
We found that the expression levels of the glycolysis-
related proteins Glut-1, hexokinase II, CAIX, and MCT4
were signiﬁcantly higher in HCNs than in FNs. FDG is
a glucose analog, and 18F-FDG is the most commonly
used radiotracer in PET/computed tomography image
acquisition. As glucose metabolism is increased in glyco-
lytic tissues, such as those with malignancies, such tissues
increase their uptake of 18F-FDG. Our ﬁndings are consis-
tent with those of a previous study showing that HCAs
exhibit a higher focal FDG uptake and higher SUVmax
compared to FA, suggesting that glycolysis is more active
in HCAs [20, 25].
There is ample evidence of the diﬀerential expression
of glycolysis-related proteins in tumors. In a genomic dis-
section study, the PI3K-AkT-mTOR and Wnt/β-catenin
pathways were shown to be activated in HCC, which
exhibited a diﬀerent molecular proﬁle than FN [18]. The
PI3K-Akt pathway plays a pivotal role in translocating
Glut-1 from the cytoplasm to the plasma membrane in
cells of endocrine organs such as the thyroid gland [26]
and pancreas [27]. Furthermore, hexokinase II was shown
to play a critical role in the proliferation of hepatocellular
carcinoma cells in an Akt signaling pathway-dependent
manner [28]. Lee et al. demonstrated that Wnt signaling
activation in breast cancer cells promotes glycolysis, which
is indirectly mediated by Snail, the transcriptional repressor
of cytochrome c oxidase [29]. Therefore, it makes sense that
the levels of glycolysis-related proteins are increased in HCC,
since PI3K-AkT-mTOR and Wnt/β-catenin pathways are
activated in these tumors. Additionally, all HCNs express
the hTERT protein [30] and TERT C228T promoter muta-
tion is common in HCNs [19]. HCCs also exhibit mark-
edly shortened telomeres [19, 30]. In previous studies,
several genes involved in the glycolytic pathway were shown
to be downregulated following TERT knockdown, suggesting
that TERT directly regulates cancer cell metabolism, espe-
cially glycolysis [31, 32]. These ﬁndings suggest that the
higher expression of glycolysis-related proteins in HCNs is
associated with TERT activity; however, additional studies
are required to clarify this.
Glycolytic marker positivity was the highest in HCCs,
followed by HCAs, FCs, and FAs. The proportions of “gly-
colysis type” samples followed the same pattern. The
expression levels of glycolysis-related proteins were higher
in carcinomas than in adenomas in both HCNs and FNs,
suggesting that cancer cells utilize glycolysis for prolifera-
tion and cell growth. In a previous study, autophagy and
senescence in cancer-associated ﬁbroblasts were shown to
contribute to tumor growth and metastasis via glycolysis
and ketone production [33]. Furthermore, glycolysis trig-
gered tumor metastasis by promoting resistance against
anoikis, which is a barrier to tumor metastasis, in mammary
epithelial cell lines [34], whereas inhibition of glycolysis in
head and neck squamous cell carcinoma suppressed tumor
growth and metastasis [35]. These ﬁndings are consistent
with our results that showed that the expression of
glycolysis-related proteins is higher in carcinomas than in
adenomas; however, the underlying mechanisms of increased
expression of glycolysis-related proteins in HCC require
further investigation.
We have demonstrated that hexokinase II positivity was
associated with large tumor size and CAIX positivity with
vascular invasion, whereas MCT4 positivity was linked to
extrathyroidal extension. Although there are no previous
studies directly comparing glycolysis activities between FN
and HCN, a previous study did evaluate glycolysis-related
protein expression in breast solid papillary carcinoma, with
results similar to ours [36]. Separately, the eﬄux of hydrogen
ions mediated by CAIX neutralizes the intracellular acidic
microenvironment that can cause the degradation of the
extracellular matrix and basement membrane [37]. There-
fore, it can be speculated that higher expression of CAIX
inﬂuences the invasive growth of tumor cells. Previously,
stromal MCT4 expression was shown to reﬂect the oxidative
stress experienced by cancer-associated ﬁbroblasts [38].
Hence, it is possible that oxidative stress is increased in
cancer-associated ﬁbroblasts in the event of extrathyroidal
extension following the aggressive growth of cancer cells,
resulting in increased expression of MCT4. Likewise, Ki-67,
proliferation marker that is expressed in tumor cells also
correlated with MCT4 in FC. However, this hypothesis
should be tested in future studies. In a previous study that
evaluated glycolysis-related protein expression in colorectal
carcinoma, tumor size was associated with hexokinase II
positivity; this makes sense because the glycolysis pathway
provides energy to cancer cells and serves as a biomoleculer
precursor of proliferation [39]. Additionally, hexokinase II
hampers cancer cell apoptosis and increases mitochondrial
stability and cell proliferation activity via PI3K-dependent
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Figure 4: Glycolysis type in follicular neoplasms and Hürthle cell
neoplasms. (FA: follicular adenoma; FC: follicular carcinoma;
HCA: Hürthle cell adenoma; HCC: Hürthle cell carcinoma).
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and PI3K-independent pathways in diﬀerent types of carci-
nomas [28, 40–43]; these data are consistent with our results.
The clinical signiﬁcance of this study is that glycolysis-
related proteins could be a potential therapeutic target in
the treatment of HCC. As lymph node metastasis in HCC
reportedly occurs in 5.3–13% of cases [19, 44–46], aggressive
surgical treatment or complete thyroidectomy is necessary
[47]. Several adjuvant therapy treatment options have been
suggested following surgical resection, including thyroxine
suppression, radioiodine, cervical radiation, directed therapy
for distant metastasis, and systemic therapy [47]. However,
the optimal treatment option is still unclear. In previous
studies, the targeting of Glut-1 [27, 48–50], hexokinase II
[51, 52], CAIX [53, 54], and MCT4 [55] suppressed tumor
growth, invasion, and metastasis. Therefore, targeting
glycolysis-related proteins in HCC might also be a promising
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Figure 5: Correlation between the expression of glycolysis-related proteins and clinicopathologic factors in Hürthle cell carcinoma.
Table 5: Correlation between the expression of glycolysis-related proteins and Ki-67 labeling index in follicular carcinomas and Hürthle
cell carcinomas.
Parameter
Follicular carcinoma (n = 112) Hürthle cell carcinoma (n = 27)
Correlation coeﬃcient p value Correlation coeﬃcient p value
GLUT1 −0.001 0.992 0.419 0.029
Hexokinase II 0.001 0.989 0.076 0.702
CAIX −0.059 0.531 0.245 0.217
MCT4 0.187 0.048 0.277 0.162
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therapy; however, this remains to be veriﬁed in future studies
that include clinical trials.
There are several limitations in this study. First, we
used immunohistochemistry to evaluate glycolysis-related
protein expression in FN and HCN, which has a limitation
in quantiﬁcation and with a possibility of interobserver
bias. In addition, the results of immunohistochemical
staining could be diﬀerent depending on antibody reactivity.
Second, as we used TMA, not whole section of the tumor
specimen to evaluate the histological examination, there
could be an extraction bias in TMA construction. However,
as TMA has shown to be a reliable method for immunohisto-
chemical analysis in clinicopathological characterization in
various tissues including thyroid gland, using TMA to
evaluate glycolysis-related protein expression might also
be applicable. Third, although glycolysis-related protein
expression was higher in HCNs and carcinomas compared
to FNs and adenomas, the prognostic implication regarding
disease-free and overall survival was not signiﬁcant. Further
investigation is required to elucidate the role of glycolysis-
related protein expression in predicting patient prognosis.
5. Conclusion
The expression levels of the glycolysis-related proteins
Glut-1, hexokinase II, CAIX, and MCT4 are higher in
HCNs compared to FNs and higher in HCCs than in
HCAs. Moreover, our results showed that overexpression
of each of these markers is associated with more aggressive
tumor characteristics, thus providing potential therapeutic
targets for HCN and FC.
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Table 6: Cox-proportional hazard analysis for disease-free survival in follicular carcinomas and Hürthle cell carcinomas.
Parameter
Univariate analysis Multivariate analysis
Odd ratio 95% CI p value Odd ratio 95% CI p value
Age≥ 45 (years) 3.656 0.789–16.934 0.097
Female sex 0.208 0.063–0.683 0.009 0.201 0.061–0.660 0.008
Tumor size >2.0 (cm) 5.363 0.686–41.910 0.109
Capsular invasion 1.320 0.169–10.316 0.790
Vascular invasion 3.204 0.938–10.946 0.063
Extrathyroidal extension 4.753 1.447–15.612 0.010 4.937 1.503–16.208 0.008
Lymph node metastasis n/a n/a n/a
GLUT-1 positivity n/a n/a n/a
Hexokinase II positivity 0.523 0.113–2.422 0.407
CAIX positivity n/a n/a n/a
MCT4 (T) positivity 0.264 0.033–2.066 0.204
Glycolysis type∗ n/a n/a n/a
n/a: not applicable. ∗Glycolysis type was deﬁned as those positive for two or more of the glycolysis related proteins.
Table 7: Cox-proportional hazard analysis for overall survival in follicular carcinomas and Hürthle cell carcinomas.
Parameter
Univariate analysis Multivariate analysis
Odd ratio 95% CI p value Odd ratio 95% CI p value
Age≥ 45 (years) 0.017 0.001–23.502 0.270
Female sex 0.326 0.053–1.994 0.225
Tumor size >2.0 (cm) 2.151 0.240–19.242 0.493
Capsular invasion 0.546 0.060–4.899 0.589
Vascular invasion 2.530 0.421–15.201 0.310
Extrathyroidal extension 3.903 0.651–23.401 0.136
Lymph node metastasis 15.742 1.723–143.770 0.014 15.742 1.723–143.770 0.014
GLUT-1 positivity n/a n/a n/a
Hexokinase II positivity n/a n/a n/a
CAIX positivity n/a n/a n/a
MCT4 (T) positivity 0.790 0.087–7.225 0.838
Glycolysis type∗ n/a n/a n/a
n/a: not applicable. ∗Glycolysis type was deﬁned as those positive for two or more of the glycolysis related proteins.
8 Disease Markers
Acknowledgments
This study was supported by a grant from the National
R&D Program for Cancer Control, Ministry of Health &
Welfare, Republic of Korea (1420080). This research was
supported by the Basic Science Research Program through
the National Research Foundation of Korea (NRF) funded
by the Ministry of Science, ICT and Future Planning
(2015R1A1A1A05001209).
References
[1] O. Warburg, “On the origin of cancer cells,” Science, vol. 123,
no. 3191, pp. 309–314, 1956.
[2] A. L. Olson and J. E. Pessin, “Structure, function, and regula-
tion of the mammalian facilitative glucose transporter gene
family,” Annual Review of Nutrition, vol. 16, pp. 235–256,
1996.
[3] M. Lehto, K. Xiang, M. Stoﬀel et al., “Human hexokinase II:
localization of the polymorphic gene to chromosome 2,”
Diabetologia, vol. 36, no. 12, pp. 1299–1302, 1993.
[4] R. Opavsky, S. Pastorekova, V. Zelnik et al., “HumanMN/CA9
gene, a novel member of the carbonic anhydrase family:
structure and exon to protein domain relationships,”Genomics,
vol. 33, no. 3, pp. 480–487, 1996.
[5] A. P. Halestrap and N. T. Price, “The proton-linked monocar-
boxylate transporter (MCT) family: structure, function and
regulation,” The Biochemical Journal, vol. 343, Part 2,
pp. 281–299, 1999.
[6] c. Centre international de recherche sur le, R. A. DeLellis, and
p. International academy of, Pathology and Genetics of
Tumours of Endocrine Organs, IARC Press, Lyon, 2004.
[7] Y. E. Nikiforov, Diagnostic Pathology and Molecular Genetics
of the Thyroid [a Comprehensive Guide for Practicing Thyroid
Pathology; Includes Online Access to Fully Searchable Text
and Image Bank!], u.a., Wolters Kluwer/Lippincott Williams
& Wilkins Health, Philadelphia, 2012.
[8] E. S. Cibas and S. Z. Ali, “The Bethesda system for reporting
thyroid cytopathology,” Thyroid, vol. 19, no. 11, pp. 1159–
1165, 2009.
[9] C. S. Grant, D. Barr, J. R. Goellner, and I. D. Hay, “Benign
Hurthle cell tumors of the thyroid: a diagnosis to be trusted?”
World Journal of Surgery, vol. 12, no. 4, pp. 488–495, 1988.
[10] N. W. Thompson, E. L. Dunn, J. G. Batsakis, and R. H.
Nishiyama, “Hurthle cell lesions of the thyroid gland,” Surgery,
Gynecology & Obstetrics, vol. 139, no. 4, pp. 555–560, 1974.
[11] M. K. McLeod, N. W. Thompson, J. L. Hudson et al., “Flow
cytometric measurements of nuclear DNA and ploidy analysis
in Hurthle cell neoplasms of the thyroid,” Archives of Surgery,
vol. 123, no. 7, pp. 849–854, 1988.
[12] E. D. Rossi, M. Martini, P. Straccia et al., “The cytologic cate-
gory of oncocytic (Hurthle) cell neoplasm mostly includes
low-risk lesions at histology: an institutional experience,”
European Journal of Endocrinology, vol. 169, no. 5, pp. 649–
655, 2013.
[13] J. A. Bishop, G. Wu, R. P. Tufano, and W. H. Westra, “Histo-
logical patterns of locoregional recurrence in Hurthle cell
carcinoma of the thyroid gland,” Thyroid, vol. 22, no. 7,
pp. 690–694, 2012.
[14] A. R. Shaha, J. P. Shah, and T. R. Loree, “Patterns of nodal and
distant metastasis based on histologic varieties in diﬀerentiated
carcinoma of the thyroid,” American Journal of Surgery,
vol. 172, no. 6, pp. 692–694, 1996.
[15] American Thyroid Association (ATA) Guidelines Taskforce
on Thyroid Nodules and Diﬀerentiated Thyroid Cancer,
D. S. Cooper, G. M. Doherty et al., “Revised American Thyroid
Association management guidelines for patients with thyroid
nodules and diﬀerentiated thyroid cancer,” Thyroid, vol. 19,
no. 11, pp. 1167–1214, 2009.
[16] S. C. Mills, M. Haq, W. J. Smellie, and C. Harmer, “Hurthle cell
carcinoma of the thyroid: retrospective review of 62 patients
treated at the Royal Marsden Hospital between 1946 and
2003,” European Journal of Surgical Oncology, vol. 35, no. 3,
pp. 230–234, 2009.
[17] Y. Kushchayeva, Q. Y. Duh, E. Kebebew, A. D'Avanzo, and
O. H. Clark, “Comparison of clinical characteristics at diag-
nosis and during follow-up in 118 patients with Hurthle cell
or follicular thyroid cancer,” American Journal of Surgery,
vol. 195, no. 4, pp. 457–462, 2008.
[18] I. Ganly, J. Ricarte Filho, S. Eng et al., “Genomic dissection of
Hurthle cell carcinoma reveals a unique class of thyroid malig-
nancy,” The Journal of Clinical Endocrinology andMetabolism,
vol. 98, no. 5, pp. E962–E972, 2013.
[19] A. M. Chindris, J. D. Casler, V. J. Bernet et al., “Clinical and
molecular features of Hurthle cell carcinoma of the thyroid,”
The Journal of Clinical Endocrinology and Metabolism,
vol. 100, no. 1, pp. 55–62, 2015.
[20] K. A. Pathak, T. Klonisch, R. W. Nason, and W. D. Leslie,
“FDG-PET characteristics of Hurthle cell and follicular
adenomas,” Annals of Nuclear Medicine, vol. 30, no. 7,
pp. 506–509, 2016.
[21] J. H. Nahm, H. M. Kim, and J. S. Koo, “Glycolysis-related pro-
tein expression in thyroid cancer,” Tumour Biology, vol. 39,
no. 3, article 1010428317695922, 2017.
[22] L. R. Henry, H. O. Lee, J. S. Lee et al., “Clinical implications of
ﬁbroblast activation protein in patients with colon cancer,”
Clinical Cancer Research, vol. 13, no. 6, pp. 1736–1741, 2007.
[23] K. Kakudo, T. Wakasa, Y. Ohta, K. Yane, Y. Ito, and
H. Yamashita, “Prognostic classiﬁcation of thyroid follicular
cell tumors using Ki-67 labeling index: risk stratiﬁcation of
thyroid follicular cell carcinomas,” Endocrine Journal, vol. 62,
no. 1, pp. 1–12, 2015.
[24] Y. Ito, M. Hirokawa, A. Miyauchi et al., “Prognostic impact
of Ki-67 labeling index in minimally invasive follicular
thyroid carcinoma,” Endocrine Journal, vol. 63, no. 10,
pp. 913–917, 2016.
[25] F. Bertagna, G. Treglia, A. Piccardo et al., “F18-FDG-PET/CT
thyroid incidentalomas: a wide retrospective analysis in three
Italian centres on the signiﬁcance of focal uptake and SUV
value,” Endocrine, vol. 43, no. 3, pp. 678–685, 2013.
[26] N. Samih, S. Hovsepian, A. Aouani, D. Lombardo, and G.
Fayet, “Glut-1 translocation in FRTL-5 thyroid cells: role of
phosphatidylinositol 3-kinase and N-glycosylation,” Endocri-
nology, vol. 141, no. 11, pp. 4146–4155, 2000.
[27] L. G. Melstrom, M. R. Salabat, X. Z. Ding et al., “Api-
genin inhibits the GLUT-1 glucose transporter and the
phosphoinositide 3-kinase/Akt pathway in human pancreatic
cancer cells,” Pancreas, vol. 37, no. 4, pp. 426–431, 2008.
[28] K. J. Ahn, H. S. Hwang, J. H. Park et al., “Evaluation of the role
of hexokinase type II in cellular proliferation and apoptosis
using human hepatocellular carcinoma cell lines,” Journal of
Nuclear Medicine, vol. 50, no. 9, pp. 1525–1532, 2009.
9Disease Markers
[29] S. Y. Lee, H. M. Jeon, M. K. Ju et al., “Wnt/Snail signaling
regulates cytochrome C oxidase and glucose metabolism,”
Cancer Research, vol. 72, no. 14, pp. 3607–3617, 2012.
[30] Y. Sugishita, M. Kammori, O. Yamada et al., “Biological dif-
ferential diagnosis of follicular thyroid tumor and Hurthle
cell tumor on the basis of telomere length and hTERT
expression,” Annals of Surgical Oncology, vol. 21, no. 7,
pp. 2318–2325, 2014.
[31] S. Bagheri, M. Nosrati, S. Li et al., “Genes and pathways down-
stream of telomerase in melanoma metastasis,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 103, no. 30, pp. 11306–11311, 2006.
[32] K. C. Low and V. Tergaonkar, “Telomerase: central regulator
of all of the hallmarks of cancer,” Trends in Biochemical
Sciences, vol. 38, no. 9, pp. 426–434, 2013.
[33] C. Capparelli, C. Guido, D. Whitaker-Menezes et al., “Autoph-
agy and senescence in cancer-associated ﬁbroblasts metaboli-
cally supports tumor growth and metastasis via glycolysis
and ketone production,” Cell Cycle, vol. 11, no. 12, pp. 2285–
2302, 2012.
[34] S. Kamarajugadda, L. Stemboroski, Q. Cai et al., “Glucose oxi-
dation modulates anoikis and tumor metastasis,” Molecular
and Cellular Biology, vol. 32, no. 10, pp. 1893–1907, 2012.
[35] H. M. Li, J. G. Yang, Z. J. Liu et al., “Blockage of glycolysis by
targeting PFKFB3 suppresses tumor growth and metastasis
in head and neck squamous cell carcinoma,” Journal of Exper-
imental & Clinical Cancer Research, vol. 36, no. 1, p. 7, 2017.
[36] J. E. Kwon, W. H. Jung, and J. S. Koo, “Expression of
glycolysis-related proteins in solid papillary carcinoma of the
breast according to basement membrane status,” Yonsei
Medical Journal, vol. 55, no. 3, pp. 576–583, 2014.
[37] P. Swietach, R. D. Vaughan-Jones, and A. L. Harris, “Regula-
tion of tumor pH and the role of carbonic anhydrase 9,”
Cancer Metastasis Reviews, vol. 26, no. 2, pp. 299–310, 2007.
[38] D. Whitaker-Menezes, U. E. Martinez-Outschoorn, Z. Lin
et al., “Evidence for a stromal-epithelial “lactate shuttle” in
human tumors: MCT4 is a marker of oxidative stress in
cancer-associated ﬁbroblasts,” Cell Cycle, vol. 10, no. 11,
pp. 1772–1783, 2011.
[39] M. Katagiri, H. Karasawa, K. Takagi et al., “Hexokinase 2 in
colorectal cancer: a potent prognostic factor associated with
glycolysis, proliferation and migration,” Histology and Histo-
pathology, vol. 32, no. 4, pp. 351–360, 2017.
[40] A. Wolf, S. Agnihotri, J. Micallef et al., “Hexokinase 2 is a key
mediator of aerobic glycolysis and promotes tumor growth in
human glioblastomamultiforme,” The Journal of Experimental
Medicine, vol. 208, no. 2, pp. 313–326, 2011.
[41] J. Chen, S. Zhang, Y. Li, Z. Tang, and W. Kong, “Hexokinase 2
overexpression promotes the proliferation and survival of
laryngeal squamous cell carcinoma,” Tumour Biology, vol. 35,
no. 4, pp. 3743–3753, 2014.
[42] J. G. Pastorino and J. B. Hoek, “Hexokinase II: the integration
of energy metabolism and control of apoptosis,” Current
Medicinal Chemistry, vol. 10, no. 16, pp. 1535–1551, 2003.
[43] Q. P. Peng, J. M. Zhou, Q. Zhou, F. Pan, D. P. Zhong, and
H. J. Liang, “Downregulation of the hexokinase II gene sen-
sitizes human colon cancer cells to 5-ﬂuorouracil,” Chemo-
therapy, vol. 54, no. 5, pp. 357–363, 2008.
[44] P. Goﬀredo, S. A. Roman, and J. A. Sosa, “Hurthle cell carci-
noma: a population-level analysis of 3311 patients,” Cancer,
vol. 119, no. 3, pp. 504–511, 2013.
[45] M. A. Guerrero, I. Suh, M. R. Vriens et al., “Age and tumor size
predicts lymph node involvement in Hurthle cell carcinoma,”
Journal of Cancer, vol. 1, pp. 23–26, 2010.
[46] A. Stojadinovic, A. Hoos, R. A. Ghossein et al., “Hurthle cell
carcinoma: a 60-year experience,” Annals of Surgical Oncology,
vol. 9, no. 2, pp. 197–203, 2002.
[47] S. Ahmadi, M. Stang, X. S. Jiang, and J. A. Sosa, “Hurthle cell
carcinoma: current perspectives,” OncoTargets and Therapy,
vol. 9, pp. 6873–6884, 2016.
[48] Y. Y. Bao, S. H. Zhou, J. Fan, and Q. Y. Wang, “Anticancer
mechanism of apigenin and the implications of GLUT-1
expression in head and neck cancers,” Future Oncology,
vol. 9, no. 9, pp. 1353–1364, 2013.
[49] S. H. Zhou, J. Fan, X. M. Chen, K. J. Cheng, and S. Q. Wang,
“Inhibition of cell proliferation and glucose uptake in human
laryngeal carcinoma cells by antisense oligonucleotides against
glucose transporter-1,”Head & Neck, vol. 31, no. 12, pp. 1624–
1633, 2009.
[50] X. M. Luo, S. H. Zhou, and J. Fan, “Glucose transporter-1 as a
new therapeutic target in laryngeal carcinoma,” The Journal of
International Medical Research, vol. 38, no. 6, pp. 1885–1892,
2010.
[51] U. Thamrongwaranggoon, W. Seubwai, C. Phoomak et al.,
“Targeting hexokinase II as a possible therapy for cholangio-
carcinoma,” Biochemical and Biophysical Research Communi-
cations, vol. 484, no. 2, pp. 409–415, 2017.
[52] A. Vartanian, S. Agnihotri, M. R. Wilson et al., “Targeting
hexokinase 2 enhances response to radio-chemotherapy in glio-
blastoma,” Oncotarget, vol. 7, no. 43, pp. 69518–69535, 2016.
[53] J. K. Ahlskog, C. E. Dumelin, S. Trussel, J. Marlind, and
D. Neri, “In vivo targeting of tumor-associated carbonic
anhydrases using acetazolamide derivatives,” Bioorganic &
Medicinal Chemistry Letters, vol. 19, no. 16, pp. 4851–
4856, 2009.
[54] F. E. Lock, P. C. McDonald, Y. Lou et al., “Targeting carbonic
anhydrase IX depletes breast cancer stem cells within the hyp-
oxic niche,” Oncogene, vol. 32, no. 44, pp. 5210–5219, 2013.
[55] S. Y. Choi, H. Xue, R. Wu et al., “The MCT4 gene: a novel,
potential target for therapy of advanced prostate cancer,”
Clinical Cancer Research, vol. 22, no. 11, pp. 2721–2733, 2016.
10 Disease Markers
